Excessive generation of reactive oxygen intermediates can induce changes in the cellular antioxidant defence system. In this study we examine the antioxidant enzyme status and the expression of fibrosis-related marker proteins in the Adriamycin model of chronic renal failure in the rat. Twenty weeks after Adriamycin treatment, rats have overt nephrotic syndrome and renal failure with development of tubulo-interstitial fibrosis and glomerulosclerosis. Lipids accumulate in blood and in both glomeruli and tubulo-interstitial tissue. Desmin and α-smooth muscle actin expression increases in glomeruli and in the tubulo-interstitial area. Renal cortex antioxidant enzyme activities are decreased 20 weeks after Adriamycin injection (to 41% for catalase, to 56% for total superoxide dismutase and to 69% for glutathione peroxidase). The mRNA levels of catalase, Cu/Zn-superoxide dismutase and glutathione peroxidase-1 evaluated by Northern blot are decreased by more than 50% for catalase, Cu/Zn-superoxide dismutase and glutathione peroxidase-1. We conclude that in the rat Adriamycin-induced model of chronic renal failure with fibrosis, the combination of decreased antioxidant enzyme status in renal cortex with high concentrations of lipids in blood and renal tissue facilitates oxidative damage. Development of fibrosis is paralleled by increased expression of desmin and α-smooth muscle actin.

Keywords:
Adriamycin, Oxidative stress, Chronic renal failure, Antioxidant enzymes, Glomerulosclerosis, Lipids, Desmin, Alpha-smooth muscle actin
1.
Ichikawa I, Kiyama S, Yoshioka T: Renal antioxidant enzymes: Their regulation and function. Kidney Int 1994;45:1–9.
2.
Nath KA, Fischereder M, Hostetter TH: The role of oxidants in progressive renal injury. Kidney Int 1994;45(suppl 45):S111–S115.
3.
McCartey MF: A central role for protein kinase C overactivity in diabetic glomerulosclerosis: Implications for prevention with antioxidants, fish oil, and ACE inhibitors. Med Hypotheses 1998;50:155–165.
4.
Studer RK, Craven PA, DeRubertis FR: Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 1997;46:918–925.
5.
Lewis MP, Norman JT: Pro-fibrogenic relevance of expression of smooth muscle actin (SMA) by renal fibroblasts: Correlation with tissue inhibitor of metalloproteinase-1 (TIMP-1) expression. J Am Soc Nephrol 1995;6:899.
6.
Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, Kasagi T, Shimizu F: Suppressive effect of superoxide dismutase on Adriamycin nephropathy. Nephron 1992;60:199–203.
7.
Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC: Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165–167.
8.
Vasquez-Vivar J, Martasek P, Hogg N, Siler Masters BS, Pritchard KA Jr, Kalyaranaman B: Endothelial nitric oxide synthase-dependent superoxide generation from Adriamycin. Biochemistry 1997;36:11293–11297.
9.
Okuda S, Oh Y, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986;29:502–510.
10.
Wanner C, Greiber S, Krämer-Guth A, Heinloth A, Galle J: Lipids and the progression of renal disease: Role of modified low density lipoprotein and lipoprotein(a). Kidney Int 1997;52(suppl 63):102–106.
11.
Reddi AS, Bollineni JS: Renal cortical expression of mRNAs for antioxidant enzymes in normal and diabetic rats. Biochem Biophys Res Commun 1997;235:598–601.
12.
Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, Koch K-M, Olbricht CJ: Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997;8:1722–1731.
13.
Washio M, Nanishi F, Okuda S, Onoyama K, Fujishima M: Alpha tocopherol improves focal glomerulosclerosis in rats with Adriamycin-induced progressive renal failure. Nephron 1994;68:347–352.
14.
Grond J, Weening JJ, Elema JD: Glomerular sclerosis in nephrotic rats: Comparison of the long-term effects of Adriamycin and aminonucleoside. Lab Invest 1984;51:277–285.
15.
Muchaneta-Kubara EC, El Nahas AM: Myofibroblast phenotypes expression in experimental scarring. Nephrol Dial Transplant 1997;12:904–915.
16.
Baudhuin P: Isolation of rat liver peroxisomes. Methods Enzymol 1974;31:358–368.
17.
Carmagnol F, Sinet P, Jerome H: Selenium dependent and non-selenium dependent glutathione peroxidases in human tissue extracts. Biochim Biophys Acta 1983;759:49–57.
18.
Marklund S, Marklund G: Involvement of the superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469–474.
19.
Tilly JL, Tilly KI: Inhibitors of oxidative stress mimic the ability of follicle-stimulating hormone to suppress apoptosis in cultured rat ovarian follicles. Endocrinology 1995;136:242–252.
20.
Lopez-De Leon A, Rojkind M: A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737–743.
21.
Spayd RW, Bruschi B, Burdick BA, Dappen GM, Eikenberry JN, Esders TW, Figueras J, Goodhue CT, LaRossa DD, Nelson RW, Rand RN, Wu T-W: Multilayer film elements for clinical analysis: Applications to representative chemical determinations. Clin Chem 1978;24:1343–1350.
22.
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470–475.
23.
Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G, Donati MB: Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982;46:16–23.
24.
Bizzi A, Gerundino M, Spina A, Tacconi MT, Veneroni E: Adriamycin causes hyperlipemia as a consequence of nephrotoxicity. Toxicol Lett 1982;18:291–300.
25.
Goodman J, Hochstein P: Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and Daunomycin. Biochem Biophys Res Commun 1977;77:797–803.
26.
Matsuda A, Kimura M, Itokawa Y: Influence of selenium deficiency on the acute cardiotoxicity of adriamycin in rats. Biol Trace Elem Res 1997;57:157–167.
27.
Chen A, Sheu LF, Ho YS, Lin YF, Chou WY, Chou TC, Lee WH: Experimental focal glomerulosclerosis in mice. Nephron 1998;78:440–452.
28.
Van den Branden C, Vamecq J, Verbeelen D, Roels F: In vivo hydrogen peroxide production in rat remnant kidney. Renal Physiol Biochem 1994;17:240–245.
29.
Van den Branden C, Verelst R, Vamecq J, Vanden Houte K, Verbeelen D: Effect of vitamin E on antioxidant enzymes, lipid peroxidation products and glomerulosclerosis in rat remnant kidney. Nephron 1997;76:77–81.
30.
Van den Branden C, Gabriels M, Vamecq J, Vanden Houte K, Verbeelen D: Carvedilol protects against glomerulosclerosis in rat remnant kidney without general changes in antioxidant enzyme status: A comparative study of two β-blocking drugs, carvedilol and propranolol. Nephron 1997;77:319–324.
31.
Verbeelen DL, Peeters P, Vanden Houte K, De Craemer D, Van den Branden C: Enalapril increases antioxidant enzyme activity in renal cortical tissue of 5/6 nephrectomized rats. Nephron 1998;80:214–219.
32.
Yoshioka T, Bills T, Moore-Jarrett T, Greene HL, Burr IM, Ichikawa I: Role of intrinsic antioxidant enzymes in renal oxidant injury. Kidney Int 1990;38:282–288.
33.
Kakar, R, Mantha SV, Radhi J, Prasad K, Kalra J: Antioxidant defense system in diabetic kidney: A time course study. Life Sci 1997;60:667–679.
34.
Tang Z, Shou I, Wang LN, Fukui M, Tomino Y: Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Nephron 1997;76:323–333.
35.
Secchi LA, Ceriello A, Griffin CA, Catena C, Amstad P, Schambelan M, Bartoli E: Renal antioxidant enzyme mRNA levels are increased in rats with experimental diabetes mellitus. Diabetologia 1997;40:23–29.
36.
Durak I, Karabacak HI, Büyükkoçak S, Burak Cimen MY, Kaçmaz M, Omeroglu E, Oztürk HS: Impaired antioxidant defense system in the kidney tissues from rabbits treated with cyclosporine: Protective effects of vitamins E and C. Nephron 1998;78:207–211.
37.
Wang LN, Fukui M, Shou I, Yaguchi Y, Funabiki K, Horikoshi S, Shirato I, Tomino Y: Detection of antioxidant enzyme activities in renal tissues of early stage IgA nephropathy in ddY mice. J Clin Lab Anal 1996;10:394–398.
38.
Kavutcu M, Canbolat O, Oztürk S, Olcay E, Ulutepe S, Ekinci C, Gökhun Durak I: Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: Effects of vitamins E and C. Nephron 1996;72:269–274.
39.
Van den Branden C, Ceyssens B, De Craemer D, De Bleser P, Hellemans K, Geerts A, Verbeelen D: Antioxidant enzyme gene expression in rats with remnant kidney induced chronic renal failure. Exp Nephrol 2000;8:91–96.
40.
de Cavanagh EMV, Inserra F, Ferder L, Romano L, Ercole L, Fraga C: Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett 1995;36:22–24.
41.
Galle J, Bengen J, Schollmeyer P, Wanner C: Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a): Role of oxygen derived radicals. Circulation 1995;92:1582–1589.
42.
Simonson MS, Walsh K, Kumar CC, Bushel P, Herman WH: Two proximal CArG elements regulate SM α-actin promoter, a genetic marker of activated phenotype of mesangial cells. Am J Physiol 1995;268:F760–F769.
43.
Johnson RJ, Iida H, Alpers CE, Majesky MW, Schwartz SM, Pritzl P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: α-Smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991;87:847–858.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.